D
Daniel R. Budman
Researcher at North Shore University Hospital
Publications - 74
Citations - 4040
Daniel R. Budman is an academic researcher from North Shore University Hospital. The author has contributed to research in topics: Chemotherapy & Cancer. The author has an hindex of 27, co-authored 74 publications receiving 3943 citations. Previous affiliations of Daniel R. Budman include University of Minnesota & North Shore-LIJ Health System.
Papers
More filters
Journal ArticleDOI
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer
Donald A. Berry,Constance Cirrincione,I. Craig Henderson,Marc L. Citron,Daniel R. Budman,Lori J. Goldstein,Silvana Martino,Edith A. Perez,Hyman B. Muss,Larry Norton,Clifford A. Hudis,Eric P. Winer +11 more
TL;DR: Among patients with node-positive tumors, ER-negative breast cancer, biweekly doxorubicin/cyclophosphamide plus paclitaxel lowers the rate of recurrence and death by more than 50% in comparison with low-dose cycloph phosphamide, doxorbicin, and fluorouracil as used in the first study.
Journal ArticleDOI
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer
Donald A. Berry,Constance Cirrincione,I. Craig Henderson,Marc L. Citron,Daniel R. Budman,Lori J. Goldstein,Silvana Martino,Edith A. Perez,Hyman B. Muss,Larry Norton,Clifford A. Hudis,Eric P. Winer +11 more
TL;DR: Among patients with node-positive tumors, ER-negative breast cancer, biweekly doxorubicin/cyclophosphamide plus paclitaxel lowers the rate of recurrence and death by more than 50% in comparison with low-dose cycloph phosphamide, doxorbicin, and fluorouracil as used in the first study.
Journal ArticleDOI
Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia.
Zev M. Sthoeger,Mariko Wakai,D B Tse,Vincent Vinciguerra,Steven L. Allen,Daniel R. Budman,Stuart M. Lichtman,Philip Schulman,Lora Weiselberg,Nicholas Chiorazzi +9 more
TL;DR: CD5-expressing B lymphocytes from patients with selected chronic lymphoproliferative disorders were used to determine whether monoclonal populations of CD5+ human B cells produce autoantibodies, and several react with dsDNA, a specificity not previously reported and often seen in association with significant autoimmune disorders.
Journal ArticleDOI
Social support as a buffer to the psychological impact of stressful life events in women with breast cancer.
Alice B. Kornblith,James E. Herndon,Enid Zuckerman,Catherine M. Viscoli,Ralph I. Horwitz,M. Robert Cooper,Lyndsay Harris,Katherine Tkaczuk,Michael C. Perry,Daniel R. Budman,Larry Norton,Jimmie C. Holland +11 more
TL;DR: Three theoretical models by which social support may influence the impact of stressful life events on cancer patients' psychological state were tested and both additive and buffering models were successful.
Journal ArticleDOI
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.
Daniel R. Budman,Neal J. Meropol,Bruno Reigner,Patrick J. Creaven,Stuart M. Lichtman,Elmer Berghorn,Joanne Behr,R. J. Gordon,Bruno Osterwalder,Thomas Griffin +9 more
TL;DR: The suggested phase II dose on a continuous 42-day dosing schedule is 1,331 mg/m2/d, and linear pharmacologic parameters of the parent compound and metabolites are demonstrated.